Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Peritoneal Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma 1

Interventions

Hyperthermic Intraperitoneal Chemotherapy 4Cytoreduction Surgical Procedures 4Cisplatin 3Oxaliplatin 2Leucovorin 2Fluorouracil 2volociximab 1vandetanib 1pembrolizumab 1pasireotide 1birinapant 1alvimopan 1Therapeutic Irrigation 1Surgical Procedures, Operative 1Saline Waters 1Paclitaxel 1Indocyanine Green 1Folfox protocol 1Docetaxel 1Chemotherapy, Adjuvant 1Cetuximab 1Carboplatin 1Capecitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Peritoneal Neoplasms × volociximab × Clear all
NCT00516841 2012-08-23

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Facet Biotech

Phase 2 Terminated
16 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡